Risk of major adverse cardiovascular events is lowest with glucagon-like-peptide-1 receptor agonists among patients with type 2 diabetes being treated with antihyperglycemics
1. In patients with type 2 diabetes (T2D), the risk of major adverse cardiovascular events (MACEs) was lowest among patients ...



